Bristol-Myers Squibb Company ( NYSE: BMY) Guggenheim Securities Inaugural Healthcare Innovation Conference November 11, 2024 10:00 AM ET Samit Hirawat - EVP, Chief Medical Officer, Global Drug ...
LifeSci Capital is acting as the lead manager for the proposed offering ... with the VC funds of Roche, Pfizer, and Bristol-Myers Squibb joining Angelini Ventures and the JDRF T1D Fund in a ...
Bristol Myers Squibb was hit on Thursday with a $6.7 billion lawsuit claiming it cheated former Celgene shareholders by ...
Bristol Myers Squibb was hit on Thursday with a $6.7 billion lawsuit claiming it cheated former Celgene shareholders by ...
Bristol Myers Squibb's stock soars after rival AbbVie reports disappointing schizophrenia-drug trial
AbbVie said it was disappointed with the results of its emraclidine trial for treating schizophrenia Bristol Myers Squibb Co. shares surged on Monday after rival AbbVie Inc. reported disappointing ...
Bristol-Myers Squibb ... patients with diabetes by building on the success Amylin has had with its GLP-1 franchise. The acquisition of Amylin by Bristol-Myers Squibb is also a unique way for ...
Bristol Myers Squibb Company BMY touched a 52-week high of $56.8 on Nov. 6. The stock is currently trading at $54.14. This biotech giant has been having a good run for the past three months ...
Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...
The drug could surpass $6 billion in yearly sales if it is approved for the various uses. More than 40 groups have signed onto a letter asking Congress to end the prescription drug price control ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback